This podcast describes how Managed Access Programs can continue treatment access for patients coming out of registration or other clinical trials who need to transition to commercial supply.
Thought Leaders:
Suzanne Gagnon, MD, Chief Medical Officer, Idis
Karen Searle PhD, Study Director, Neuroscience & General Medicine (NGM), Eisai Global Clinical Development
Michelle Gee, PhD, Director, Neuroscience & General Medicine (NGM), Eisai Global Clinical Development
Download Podcast
Download Podcast Transcript
Download related case study
See All PharmaVOICE Podcasts
See All PharmaVOICE White Papers
Posts
